Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: the role of activated protein C in severe sepsis

Is it likely that the data emanating from the multinational phase 3 trial of drotrecogin alfa activated in severe sepsis will provide substantiation of the several mechanisms of action potentially active in this treatment. The wealth of information gained through this type of investigation will provide a much more substantial position from which to conduct further studies of the mechanisms of diffuse tissue injury and treatment modalities for severe sepsis.